MA1-10148

antibody from Invitrogen Antibodies

Targeting: IGF2R CD222, CI-M6PR, CI-MPR, CIMPR, M6P-R, MPR1, MPR300, MPRI

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA1-10148

Provider

Invitrogen Antibodies

Product name

IGF2R Monoclonal Antibody (MEM-238), PE

Antibody type

Monoclonal

Antigen

Recombinant full-length protein

Description

This antibody recognizes an epitope between domains 2 and 5 of CD222 (IGF2 receptor), a ubiquitously expressed 250 kDa multifunctional type I transmembrane protein. The majority of CD222 is found in the late endosomal/prelysosomal compartment, 5-10% in the plasma membrane and the truncated (220 kDa) form of CD222 is present in human and bovine serum.

Reactivity

Human

Host

Mouse

Conjugate

Yellow dye

Isotype

IgG

Antibody clone number

MEM-238

Vial size

100 Tests

Storage

4° C, store in dark, DO NOT FREEZE!

References

Submitted references

Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death.

Draganov D, Gopalakrishna-Pillai S, Chen YR, Zuckerman N, Moeller S, Wang C, Ann D, Lee PP
Scientific reports 2015 Nov 10;5:16222

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometry analysis (intracellular staining) of human peripheral blood with anti-CD222 (MEM-238) PE Monoclonal antibody (Product # MA1-10148).

Conjugate

Yellow dye

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 6 Ivermectin induces autophagy. ( A ) Ivermectin induces autophagy in breast cancer cells. MDA-MB-231 GFL-LC3 cells were treated with different doses of Ivermectin for 24 h and formation of green fluorescent puncta was evaluated by confocal fluorescence microscopy. ( B ) Western blot confirming the induction of autophagy in both murine and human breast cancer cells, as evidenced by LC3 lipidation and autophagic degradation of p62(SQSTM1). ( C ) Ivermectin up-regulates surface exposure of M6P receptor (top panel) but does not impact the exposure of Calreticulin (CRT) (bottom panel). MDA-MB-231 cells (triplicates) were treated with different doses of Ivermectin for up to 24 h and surface stained with antibody-specific for the human M6P receptor versus isotype control. Similarly, 4T1.2 and MB231 cells were treated with different doses of Ivermectin for 4-24 h, and were stained with an antibody specific for both human and mouse CRT versus isotype control. Mean fluorescence intensity (MFI) values and ratios versus isotype control were calculated after gating on live/membrane-intact cells. ( D ) Ivermectin (32 muM) induces release of HMGB1 from murine and human TNBC cells (triplicates). ( E ) Ivermectin treatment induces release of cytosolic LDH, data are normalized to maximum release (lysis). Asterisk (*) indicates p < 0.05 relative to untreated or Ivermectin alone controls, respectively.

Conjugate

Yellow dye